Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) EBITDA Margin (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed EBITDA Margin for 9 consecutive years, with 5874.49% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA Margin fell 113005.0% year-over-year to 5874.49%, compared with a TTM value of 7621.58% through Jun 2025, down 178449.0%, and an annual FY2025 reading of 4649.3%, up 330280.0% over the prior year.
  • EBITDA Margin was 5874.49% for Q2 2025 at VYNE Therapeutics, down from 4272.77% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 3234.58% in Q2 2021 and bottomed at 27531.03% in Q4 2022.
  • Average EBITDA Margin over 5 years is 7552.24%, with a median of 5824.96% recorded in 2023.
  • The sharpest move saw EBITDA Margin plummeted -2429111bps in 2022, then soared 1942314bps in 2023.
  • Year by year, EBITDA Margin stood at 3239.93% in 2021, then tumbled by -750bps to 27531.03% in 2022, then skyrocketed by 71bps to 8107.89% in 2023, then plummeted by -77bps to 14328.57% in 2024, then soared by 59bps to 5874.49% in 2025.
  • Business Quant data shows EBITDA Margin for VYNE at 5874.49% in Q2 2025, 4272.77% in Q1 2025, and 14328.57% in Q4 2024.